Description

Dr. Nate Bergman quickly summarizes the story up the FDA's recent "accelerated approval" of Biogen's - Aducanumab (brand named, Aduhelm). He ends off with surprise about why he is excited about the approval...and it's probably not what you think! A quick, but useful listen.

In this episode we talk about…

• The terms of the approval of the drug
• What Aducanumab was able to accomplish in Alzheimer's patients
• The circumstances that led to Aducanumab being approved
• Some of the problems that arise with Aducanumab
• Why I am excited about Aducanumab